Bank of Nova Scotia
RLMD icon

Bank of Nova Scotia’s Relmada Therapeutics RLMD Stock Holding History

Bank of Nova Scotia’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$213K Buy
+30,600
New +$145K ﹤0.01% 1023

Other funds holding RLMD

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
SSC
Spruce Street Capital New York $416M AUM
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Bank of Nova Scotia's RLMD Position: Q1 2026 in Review

Bank of Nova Scotia opened a new position in Relmada Therapeutics (RLMD) in Q1 2026: 30,600 shares worth $213K. The stake represents ﹤0.01% of the portfolio and ranks #1023 among its holdings.

103 funds tracked by Wall St. Rank hold RLMD as of Q1 2026.

  • Bank of Nova Scotia held 30,600 shares of Relmada Therapeutics worth $213K as of Q1 2026.
  • Relmada Therapeutics was a new Bank of Nova Scotia position in Q1 2026.
  • Relmada Therapeutics made up ﹤0.01% of Bank of Nova Scotia's portfolio in Q1 2026, its #1023 holding.
  • 103 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q1 2026.

Based on Bank of Nova Scotia's 13F filing for Q1 2026, filed 14 May 2026.